Gilead Sciences (GILD) reachead $88.08 at the closing of the latest trading day, reflecting a -0.77% change compared to its last close.

Besides Wall Street's top -and-bottom-line estimates for Gilead (GILD), review projections for some of its key metrics to gain a deeper understanding...

A flexible silicone ring that slowly releases antiretrovirals is one of just two long-acting HIV prevention products registered for use in South...

GILD's Q3 earnings and sales beat estimates on higher HIV, Veklury, oncology and liver disease drug sales. The stock is trading up.

We need nothing less than disruptive action to ensure everyone who wants access to affordable lenacapavir can get it.

Decree 141/2024/NĐ-CP specifies details on harm reduction interventions in HIV prevention, excluding measures already prescribed in Decree No....

Nykredit has reported its highest earnings ever, reaching nearly nine billion Danish kroner in the first nine months of the year. According to...

Pre-surgery treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab led to tumor control in 55% of patients with stage 3...

MRNA reports better-than-expected third-quarter earnings. It reiterates the guidance of product sales to between $3 billion and $3.5 billion for 2024.

Novo Nordisk earned 72.8 billion kroner in operating profit over the first nine months of 2024, an 18 percent increase from last year, according to...